theory clinical_35_2
imports Main

begin

typedecl entity
typedecl event

consts
  NotchInhibitor :: "entity ⇒ bool"
  BetaCateninLevel :: "entity ⇒ bool"
  Decrease :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  CTNNB1Mutation :: "entity ⇒ bool"
  CellProliferation :: "entity ⇒ bool"
  BetaCatenin :: "entity ⇒ bool"
  Promote :: "event ⇒ bool"
  Via :: "event ⇒ entity ⇒ bool"
  InDevelopment :: "entity ⇒ bool"
  Reduce :: "event ⇒ bool"
  Counteract :: "event ⇒ bool"
  Cause :: "entity ⇒ entity ⇒ bool"
  EffectiveInTreating :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Notch inhibitors decrease the level of β-catenin. *)
axiomatization where
  explanation_1: "∀x y e. NotchInhibitor x ∧ BetaCateninLevel y ⟶ (Decrease e ∧ Agent e x ∧ Patient e y)"

(* Explanation 2: Activating mutations of CTNNB1 promote proliferation of cells via β-catenin. *)
axiomatization where
  explanation_2: "∀x y z e. CTNNB1Mutation x ∧ CellProliferation y ∧ BetaCatenin z ⟶ (Promote e ∧ Agent e x ∧ Patient e y ∧ Via e z)"

(* Explanation 3: There are Notch inhibitors in development. *)
axiomatization where
  explanation_3: "∃x. NotchInhibitor x ∧ InDevelopment x"

(* Explanation 4: Reducing the level of β-catenin can counteract the proliferation of cells caused by activating mutations of CTNNB1. *)
axiomatization where
  explanation_4: "∀x y z e1 e2. BetaCateninLevel x ∧ CellProliferation y ∧ CTNNB1Mutation z ⟶ (Reduce e1 ∧ Agent e1 x ∧ Counteract e2 ∧ Agent e2 z ∧ Patient e2 y ∧ Cause z y)"

theorem hypothesis:
  assumes asm: "NotchInhibitor x ∧ Patient e y ∧ CTNNB1Mutation y"
  (* Hypothesis: A Notch inhibitor may be effective in treating patients with activating CTNNB1 mutations. *)
  shows "∃x y. NotchInhibitor x ∧ Patient e y ∧ CTNNB1Mutation y ⟶ EffectiveInTreating x y"
proof -
  (* From the premise, we have known information about Notch inhibitors and CTNNB1 mutations. *)
  from asm have "NotchInhibitor x ∧ CTNNB1Mutation y" by simp
  (* Explanation 1 states that Notch inhibitors decrease the level of β-catenin. *)
  (* Explanation 4 states that reducing the level of β-catenin can counteract the proliferation of cells caused by activating mutations of CTNNB1. *)
  (* There is a logical relation Implies(A, D), Implies(Notch inhibitors decrease the level of β-catenin, Reducing the level of β-catenin can counteract the proliferation of cells caused by activating mutations of CTNNB1). *)
  (* From the known information and logical relations, we can infer that Notch inhibitors can counteract the proliferation of cells caused by activating mutations of CTNNB1. *)
  then have "Counteract e2 ∧ Agent e2 y ∧ Patient e2 y" sledgehammer
  (* If Notch inhibitors can counteract the proliferation of cells, they may be effective in treating patients with activating CTNNB1 mutations. *)
  then have "EffectiveInTreating x y" <ATP>
  then show ?thesis <ATP>
qed

end
